


## Curriculum Vitae Form

<b>Name</b>	<b>Dermot P.B. McGovern</b>	
<b>Country</b>	<b>USA</b>	
<b>Organization</b>	<b>Cedars Sinai Medical Center Inflammatory Bowel Disease Center</b>	
<b>Current Position</b>	<b>Joshua L and Lisa Z Greer Endowed Chair in IBD Genetics. Professor of Medicine Director, Precision Medicine Initiative F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute Department of Medicine</b>	

### Educational Background

- Medical School: St Mary's Hospital Medical School, 1993
- GI Fellowship: Oxford Deanery
- Doctorate: University of Oxford, 2005
- Fellowship: Oxford Deanery, UK, 2006

### Professional Experience

Dermot McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai, Los Angeles.. Dr McGovern is the Director of Translational Medicine at the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai and directs the Cedars-Sinai Precision Medicine Initiative. He holds the Joshua and Lisa Greer Endowed Chair in IBD Genetics. Dr. McGovern's clinical interests include the extra-intestinal complications of IBD and the overlap between IBD and other immune-mediated and metabolic diseases. His group study genomics and other '-omic' technologies to try and better understand the natural history of IBD including response to therapies.

### Professional Organizations

American Society of Clinical Investigation  
Royal College of Physicians of London  
American Gastroenterology Association  
Crohns' and Colitis Foundation  
American Society of Human Genetics

### Main Scientific Publications

1. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients

- 
- with active luminal Crohn's disease: a prospective, multicentre, cohort study. *Lancet Gastroenterol Hepatol.* 2019 May;4(5):341-353.
2. Limon JJ, Tang J, Li D, Wolf AJ, Michelsen KS, Funari V, Gargus M, Nguyen C, Sharma P, Maymi VI, Iliev ID, Skalski JH, Brown J, Landers C, Borneman J, Braun J, Targan SR, McGovern DPB, Underhill DM. Malassezia is Associated with Crohn's Disease and Exacerbates Colitis in Mouse Models. *Cell Host & Microbe.* 2019 Mar 13;25(3):377-388.e6.
  3. Potdar AA, Li D, Haritunians T, VanDussen KL, Fiorino MF, Liu TC, Stappenbeck TS, Fleshner P, Targan SR, McGovern DPB, Bilsborough J. Ileal Gene Expression Data from Crohn's Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups. *J Crohns Colitis.* 2019 Mar 16. pii: jjz021.
  4. Li D, Haritunians T, Landers C, Potdar AA, Yang S, Huang H, Schumm LP, Daly M, Targan SR, McGovern DPB. Late-Onset Crohn's Disease Is A Subgroup Distinct in Genetic and Behavioral Risk Factors With UC-Like Characteristics. *Inflamm Bowel Dis.* 2018 Oct 12;24(11):2413-2422.
  5. Yang SK, Hong M, Oh H, Low HQ, Jung S, Ahn S, Kim Y, Baek J, Lee CH, Kim E, Kim KM, Ye BD, Kim KJ, Park SH, Lee HS, Lee I, Shin HD, Han B, McGovern DP, Liu J, Song K. Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. *Gastroenterology.* 2016 Dec;151(6):1096-1099.
  6. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, Haritunians T, Ye BD, Kim KJ, Park SH, Park SK, Yang DH, Dubinsky M, Lee I, McGovern DP, Liu J, Song K. A common missense variant in *NUDT15* confers susceptibility to thiopurine-induced leukopenia. *Nat Genet.* 2014 Sep;46(9):1017-20.
-